Literature DB >> 25190531

Comment on 'Herpes zoster ophthalmicus reduction: implementation of shingles vaccination in the UK'.

L Clearkin1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25190531      PMCID: PMC4268452          DOI: 10.1038/eye.2014.204

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

Review 1.  Treatment and prevention of postherpetic neuralgia.

Authors:  Robert H Dworkin; Kenneth E Schmader
Journal:  Clin Infect Dis       Date:  2003-03-13       Impact factor: 9.079

2.  Herpes zoster ophthalmicus reduction: implementation of shingles vaccination in the UK.

Authors:  A Potts; G J Williams; J A Olson; K G J Pollock; H Murdoch; J C Cameron
Journal:  Eye (Lond)       Date:  2014-03       Impact factor: 3.775

3.  Acyclovir and steroids in herpes zoster keratouveitis.

Authors:  R J Marsh; M Cooper
Journal:  Br J Ophthalmol       Date:  1984-12       Impact factor: 4.638

4.  High-dose oral acyclovir in acute herpes zoster ophthalmicus: the end of the corticosteroid era.

Authors:  C P Herbort; E R Buechi; B Piguet; L Zografos; P Fitting
Journal:  Curr Eye Res       Date:  1991       Impact factor: 2.424

5.  A comparison of topical acyclovir with steroids in the treatment of herpes zoster keratouveitis.

Authors:  J McGill; C Chapman
Journal:  Br J Ophthalmol       Date:  1983-11       Impact factor: 4.638

  5 in total
  1 in total

1.  Response to Dr Clearkin.

Authors:  G Williams; J A Olson
Journal:  Eye (Lond)       Date:  2014-09-05       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.